Improving use of proton pump inhibitors with dual antiplatelet therapy in patients admitted with acute coronary syndrome

• Published in: BMJ open quality Vol. 11; no. 4; p. e001956
• Main Authors: Jinadu, Tomilola, Radhakrishnan, Ashwin, Fan, Lampson
• Format: Journal Article
• Language: English
• Published: England BMJ Publishing Group LTD 01.12.2022; BMJ Publishing Group
• Subjects: Acute Coronary Syndrome - drug therapy; Acute Coronary Syndrome - epidemiology; Acute coronary syndromes; Anemia; Aspirin; Cardiology; Cardiovascular disease; Clinical practice guidelines; Coronary vessels; Data collection; Drug Therapy, Combination; Gastrointestinal Hemorrhage - chemically induced; Gastrointestinal Hemorrhage - drug therapy; Humans; Ischemia; Mortality; Multidisciplinary teams; Platelet Aggregation Inhibitors - therapeutic use; Proton Pump Inhibitors - adverse effects; Proton Pump Inhibitors - therapeutic use; Quality improvement; Quality Improvement Report; Vein & artery diseases; United Kingdom > UK; Clinical pharmacology; Clinical practice guidelines; Healthcare quality improvement; PDSA
• ISSN: 2399-6641; 2399-6641
• DOI: 10.1136/bmjoq-2022-001956

Acute coronary syndrome (ACS) is one of the leading causes of morbidity and mortality with a major impact on healthcare resources and expenditure. Dual antiplatelet therapy (DAPT) is recommended for the treatment of ACS. DAPT is associated with an increased risk of gastrointestinal (GI) bleeding, which is seen in 1.2%–2.4% of patients on DAPT and associated with fivefold increase in mortality at 30 days and fourfold increase at 1 year. European Society of Cardiology guidelines recommend that patients on DAPT should also be prescribed a proton pump inhibitor (PPI) to reduce the risk of GI bleeding. We assessed compliance with this recommendation on the cardiology ward of our tertiary cardiac unit. At baseline, only 56% of patients on DAPT were coprescribed a PPI. We subsequently devised and delivered a service improvement project (three completed audit cycles) to improve concomitant prescription of PPI, with the aim of achieving 100% compliance with the guidelines. We introduced low-cost interventions that included educational sessions for junior doctors, cardiac nursing staff and pharmacists, as well as posters which served as visual prompts for discharging doctors. We also initiated a protocol that the pharmacy team clarify with the discharging doctor whether a patient on DAPT should also be on PPI, before the discharge summary is finalised. Consequently, 100% of patients on DAPT were coprescribed PPI within fourteen weeks of the onset of our intervention. This improvement was sustained across a subsequent cohort of junior doctors. Our interventions should help to reduce the risk of GI bleeding in this population.